ATROPOS: Survival Analysis of ICI-associated Myocarditis

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for records of people with cancer who got heart muscle inflammation (myocarditis) linked to immune checkpoint inhibitor drugs. It uses data from an international registry.

Nem

All sexes can join.

A betegség stádiuma

Possible, probable or definite immune checkpoint inhibitor-associated myocarditis, as recorded in the international registry.

Korábbi kezelés

Must have received at least one immune checkpoint inhibitor.

A részvétel fő kizáró okai

• Duplicate records
• Not enough data to class the case as myocarditis
• Record or patient withdrawn from research use
• Unsolved data-quality problems that keep the record out of the final analysis

A regiszter feltételei, szó szerint

Mit akar kideríteni a vizsgálat

ATROPOS is an international, registry-based observational study of cancer patients with immune checkpoint inhibitor-associated myocarditis (ICI-M). The study evaluates whether immunosuppressive treatment strategies, including first-line glucocorticoids and subsequent second-line immunosuppressants, are associated with overall mortality, and whether these associations vary according to myocarditis severity. The target number of cases to be included is 1500 spanning from at least 160 centers, located in at least 18 countries. Analyses will adjust for clinically relevant confounders and may use time-dependent survival models where appropriate.